Showing results (1111-1120 of 1,547) with videos related to
Sort By:
Pageof 155
Journal of Neuro-Oncology|October 11, 2011
Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade gliomaJ Drappatz, E Q Lee, S Hammond, et al.Journal of Neuro-Oncology|October 5, 2017
Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab aloneNils D Arvold, Diana D Shi, Ayal A Aizer, et al.International Journal of Radiation Oncology, Biology, Physics|June 3, 2008
A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiformeJan Drappatz, Eric T Wong, David Schiff, et al.Plos One|June 22, 2012
DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissuesJustin M Craig, Natalie Vena, Shakti Ramkissoon, et al.Neuro-Oncology Practice|February 7, 2025
<i>G</i>lioma <i>r</i>esource <i>o</i>utreach <i>w</i>ith <i>s</i>upport: A program to identify and initiate supportive care interventions for unmet needs among adult lower-grade glioma patientsRachel Garcia Fox, Ugonma N Chukwueke, Timothy Sannes, et al.Neuro-Oncology|November 1, 2020
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trialsBenjamin M Ellingson, Matthew S Brown, Jerrold L Boxerman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2015
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type GlioblastomasMaite Verreault, Charlotte Schmitt, Lauriane Goldwirt, et al.Neuro-Oncology|August 8, 2018
Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progressionRaymond Y Huang, Prashin Unadkat, Wenya Linda Bi, et al.Neuro-Oncology|February 27, 2023
Diagnosis and management of complications from the treatment of primary central nervous system tumors in adultsMichael Weller, Emilie Le Rhun, Martin Van den Bent, et al.Journal of Neuro-Oncology|November 18, 2016
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastomaJayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, et al.Pageof 155